Stockscreener 앱 받기
4.225
11.24%
-0.535
시간 외 거래:
4.36
0.135
+3.20%
전일 마감가:
$4.76
열려 있는:
$4.68
하루 거래량:
555.94K
Relative Volume:
0.90
시가총액:
$278.25M
수익:
-
순이익/손실:
$-26.25M
주가수익비율:
-10.31
EPS:
-0.4099
순현금흐름:
$-20.05M
1주 성능:
-3.32%
1개월 성능:
+60.04%
6개월 성능:
+38.98%
1년 성능:
+48.25%
1일 변동 폭
$4.15
$4.71
1주일 범위
$4.01
$5.55
52주 변동 폭
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
명칭
Galectin Therapeutics Inc
전화
678-620-3186
주소
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.225 | 313.48M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 121.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
678.94 | 69.66B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
857.97 | 53.99B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
179.18 | 39.21B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.15 | 37.27B | 4.29B | 577.22M | 641.34M | 4.2086 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 재개 | H.C. Wainwright | Buy |
| 2020-08-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-13 | 개시 | B. Riley FBR | Buy |
| 2017-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-19 | 개시 | ROTH Capital | Buy |
| 2017-03-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | 다운그레이드 | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-09-21 | 개시 | H.C. Wainwright | Buy |
| 2014-08-01 | 다운그레이드 | Aegis Capital | Buy → Hold |
| 2014-07-30 | 재확인 | MLV & Co | Buy |
| 2014-07-29 | 재확인 | MLV & Co | Buy |
| 2014-04-02 | 재확인 | MLV & Co | Buy |
| 2014-02-10 | 재확인 | Aegis Capital | Buy |
| 2014-01-09 | 재확인 | Aegis Capital | Buy |
| 2013-12-03 | 개시 | MLV & Co | Buy |
| 2013-08-19 | 재확인 | Aegis Capital | Buy |
모두보기
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock - Investing.com
Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com - Investing.com Canada
Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan - Stock Titan
Can Galectin Therapeutics (NASDAQ:GALT) Regain Confidence? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research - MarketBeat
Price to book forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
$Galectin Therapeutics (GALT.US)$ - Moomoo
$Galectin Therapeutics (GALT.US)$ put CMO at the table with who at solar? - Moomoo
GALT jumps 11% on FDA alignment for belapectin phase III path in MASH - MSN
Enterprise value to revenue forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Price to sales forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review
Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock - Investing.com
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock By Investing.com - Investing.com Nigeria
Galectin Therapeutics director sells $150,890 in common stock By Investing.com - Investing.com South Africa
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity - Stock Titan
Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Harold Shlevin files Form 144: GALT (NASDAQ) sale of 7,732 shares - Stock Titan
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2500 Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Value Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Completeness Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000 Growth Benchmark - marketscreener.com
If you're not following me on stocktwits you probably should My money is on a partnership with Madrigal - Moomoo
GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN
Form 144 GALECTIN THERAPEUTICS INC For: 26 June - Investing.com UK
Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 144 GALECTIN THERAPEUTICS INC For: 26 June By Investing.com - Investing.com Nigeria
GALT (NASDAQ: GALT) Rule 144 notice: Khurram Jamil reports share disposals - Stock Titan
Form 144 GALECTIN THERAPEUTICS INCORPORATED For: 26 June By Investing.com - Investing.com Canada
[144] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
GALTGalectin Therapeutics Inc Revenue Breakdown - Finviz
$Galectin Therapeutics (GALT.US)$ The FIB Strikes Again!! - Moomoo
Galectin Therapeutics Inc. Actuals & Estimates (FWB:PHPN) - TradingView
GALT Forecast — Price Target — Prediction for 2027 - TradingView
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares - Investing.com
Form 4 Galectin Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan - Stock Titan
PHPN Forecast — Price Target — Prediction for 2027 - TradingView
Galectin Therapeutics(GALT) Stock Options Chain | Quotes & News - Moomoo
FDA alignment reduces risk for Galectin Therapeutics' belapectin Phase 3 trial, keeping it a buy. - Pluang
Galectin De-Risks Belapectin Path With FDA AlignmentSets Stage For Phase 3 Upside - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
Galectin Therapeutics Inc (GALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.36%
2.75%
자본화:
|
볼륨(24시간):